Evidence map›Paper›PMID 25325454›Full record

Trial reportSleep2015

Effects of estradiol and venlafaxine on insomnia symptoms and sleep quality in women with hot flashes.

Kristine E Ensrud, Katherine A Guthrie, Chancellor Hohensee, Bette Caan, Janet S Carpenter, Ellen W Freeman, Andrea Z LaCroix, Carol A Landis, JoAnn Manson, Katherine M Newton and 6 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Sleep, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01418209 (MsFLASH-03), which is not on this map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01418209 nacompletednot on this map

MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and the SNRI Venlafaxine XR for Treatment of Menopausal Symptoms

TypeinterventionalSponsorFred Hutchinson Cancer CenterRan2011 to 2013Enrolled339ConditionsHot Flashes, Menopause, Vasomotor DisturbanceArmsLow-dose 17-ß-estradiol with progesterone taper, Venlafaxine XR, Placebo
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Caloric Restriction, the Menstrual Cycle, and Sleep in Women Without Obesity.The Journal of clinical endocrinology and metabolism · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Insomnia among Cancer Patients in the Real World: Optimising Treatments and Tailored Therapies.International journal of environmental research and public health · 2023
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kristine E EnsrudDepartment of Medicine and Division of Epidemiology & Community Health, University of Minnesota, Minneapolis, MN: Center for Chronic Disease Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN.
Katherine A GuthrieFred Hutchinson Cancer Research Center, Seattle WA.
Chancellor HohenseeFred Hutchinson Cancer Research Center, Seattle WA.
Bette CaanDivision of Research, Kaiser Permanente, Oakland, CA.
Janet S CarpenterSchool of Nursing, Indiana University, Indianapolis, IN.
Ellen W FreemanDepartments of Obstetrics, Gynecology and Psychiatry, University of Pennsylvania, Philadelphia, PA.
Andrea Z LaCroixFred Hutchinson Cancer Research Center, Seattle WA.
Carol A LandisDepartment of Biobehavioral Nursing and Health Systems, University of Washington, Seattle, WA.
JoAnn MansonDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Katherine M NewtonGroup Health Research Institute, Seattle WA.
Julie OtteSchool of Nursing, Indiana University, Indianapolis, IN.
Susan D ReedDepartment of Medicine, University of Washington, Seattle, WA.
Jan L ShifrenDepartment of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Barbara SternfeldDivision of Research, Kaiser Permanente, Oakland, CA.
Nancy F WoodsDepartment of Biobehavioral Nursing and Health Systems, University of Washington, Seattle, WA.
Hadine JoffeDepartment of Psychiatry, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA.

Funding

Menopausal Symptoms Initiative-Finding Lasting Answers for Sweats and Hot FlashesU01AG032699 · NIA · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GUTHRIE, KATHERINE ADAMS, LACROIX, ANDREA Z. · 2008 to 2012
$13.5M
MsFLASH: Living a Healthy MenopauseR01AG048209 · NIA · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GUTHRIE, KATHERINE ADAMS, LACROIX, ANDREA Z. · 2015 to 2019
$7.2M
MSI-FLASH: Relative Efficacy of Hormonal and Non-Hormonal Interventions for VMSU01AG032700 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI COHEN, LEE S, JOFFE, HADINE · 2008 to 2012
$1.7M
MSI FLASH: An RCT of Yoga and Ultra Low-Dose Estrogen Gel for Vasomotor SymptomsU01AG032682 · NIA · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI NEWTON, KATHERINE M. · 2008 to 2012
$1.7M
Efficacy of an SSRI for Menopausal Symptoms in Perimenopausal WomenU01AG032656 · NIA · UNIVERSITY OF PENNSYLVANIA · PI FREEMAN, ELLEN W · 2008 to 2012
$1.5M
MSI-FLASH: Paced Respiration for Breast Cancer SurvivorsU01AG032659 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI CARPENTER, JANET S · 2008 to 2012
$1.5M
MSI-FLASH: An Exercise Intervention for Women with Menopausal SymptomsU01AG032669 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI CAAN, BETTE J · 2008 to 2012
$1.5M
NIA NIH HHS R01 AG048209NIA NIH HHS U01 AG032656NIA NIH HHS U01AG032659NIA NIH HHS U01AG032669NIA NIH HHS U01AG032682NIA NIH HHS U01 AG032699NIA NIH HHS U01AG032699NIA NIH HHS U01AG032700
6 · The paper itself

Abstract

STUDY

objectivesDetermine effects of low-dose estradiol and low-dose venlafaxine on self-reported sleep measures in menopausal women with hot flashes.

design3-arm double-blind randomized trial. Participants assigned in a 2:2:3 ratio to 17β estradiol 0.5 mg/day (n = 97), venlafaxine XR 75 mg/day (n = 96), or placebo (n = 146) for 8 weeks.

settingAcademic research centers.

participants339 community-dwelling perimenopausal and postmenopausal women with ≥2 bothersome hot flashes per day. MEASUREMENTS AND

resultsInsomnia symptoms (Insomnia Severity Index [ISI]) and sleep quality (Pittsburgh Sleep Quality Index [PSQI]) at baseline, week 4 and 8; 325 women (96%) provided ISI data and 312 women (92%) provided PSQI data at baseline and follow-up. At baseline, mean (SD) hot flash frequency was 8.1/day (5.3), mean ISI was 11.1 (6.0), and mean PSQI was 7.5 (3.4). Mean (95% CI) change from baseline in ISI at week 8 was -4.1 points (-5.3 to -3.0) with estradiol, -5.0 points (-6.1 to -3.9) with venlafaxine, and -3.0 points (-3.8 to -2.3) with placebo (P overall treatment effect vs. placebo 0.09 for estradiol and 0.007 for venlafaxine). Mean (95% CI) change from baseline in PSQI at week 8 was -2.2 points (-2.8 to -1.6) with estradiol, -2.3 points (-2.9 to -1.6) with venlafaxine, and -1.2 points (-1.7 to -0.8) with placebo (P overall treatment effect vs. placebo 0.04 for estradiol and 0.06 for venlafaxine).

conclusionsAmong perimenopausal and postmenopausal women with hot flashes, both low dose oral estradiol and low-dose venlafaxine compared with placebo modestly reduced insomnia symptoms and improved subjective sleep quality. CLINICAL

trial registrationNCT01418209 at www.clinicaltrials.gov.

Indexed as

CyclohexanolsDouble-Blind MethodEstradiolEstrogensFemaleHot FlashesHumansMenopauseMiddle AgedPerimenopauseSleepSleep Initiation and Maintenance DisordersVenlafaxine HydrochlorideCyclohexanolsEstradiolEstrogensVenlafaxine Hydrochlorideestradiolhot flashesmenopauserandomized trialsleepvenlafaxine

Identifiers

PMID25325454
PMCPMC4262961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.